about
Current management and perspectives for HCV recurrence after liver transplantationFrom immunosuppression to tolerancePractical Recommendations for Long-term Management of Modifiable Risks in Kidney and Liver Transplant Recipients: A Guidance Report and Clinical Checklist by the Consensus on Managing Modifiable Risk in Transplantation (COMMIT) Group.Safety, tolerability, and efficacy of everolimus in de novo liver transplant recipients: 12- and 36-month results.Hepatitis and solid organ transplantation.The difficulties of managing severe hepatitis B virus reactivation.Liver transplantation in patients with HIV infection.Liver transplantation for hepatitis B virus-related liver disease: indications, prevention of recurrence and results.Spontaneous Splenorenal Shunt in Liver Transplantation: Results of Left Renal Vein Ligation Versus Renoportal Anastomosis.Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014.Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?Evolving strategies to prevent HBV recurrence.Place of the liver biopsy in liver transplantation.Aspects of hepatitis C virus infection relating to liver transplantation.A decision analysis model identifies the interval of efficacy for transarterial chemoembolization (TACE) in cirrhotic patients with hepatocellular carcinoma awaiting liver transplantation.Etiology and prognosis of fulminant hepatitis in adults.Liver transplantation in viral hepatitis: prevention of recurrence.Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL).Model for end-stage liver disease exceptions in the context of the French model for end-stage liver disease score-based liver allocation system.Toward optimizing the indications for orthotopic liver transplantation in hepatocellular carcinoma.Hepatitis C virus treatment pre- and post-liver transplantation.Liver transplantation in delta virus infection.Treatment of patients with HBV-related decompensated cirrhosis and liver transplanted patients.Management of HCV transplant patients with triple therapy.Outcome of patients with cirrhosis requiring mechanical ventilation in ICU.Rational Basis for Optimizing Short and Long-term Hepatitis B Virus Prophylaxis Post Liver Transplantation: Role of Hepatitis B Immune Globulin.Long-term outcome in liver transplantation candidates with portopulmonary hypertension.Acute Liver Failure/Injury Related to Drug Reaction With Eosinophilia and Systemic Symptoms: Outcomes and Prognostic Factors.ELITA consensus statements on the use of DAAs in liver transplant candidates and recipients.Predictors of response to tenofovir disoproxil fumarate plus peginterferon alfa-2a combination therapy for chronic hepatitis B.Persistence of yellow fever vaccine-induced antibodies after solid organ transplantation.Characteristics of patients with chronic hepatitis B in France: predominant frequency of HBe antigen negative cases.'EUROHEP' consensus report on the management of liver transplantation for hepatitis B virus infection. European Concerted Action on Viral Hepatitis.Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection.Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation.Multicentre experience using daclatasvir and sofosbuvir to treat hepatitis C recurrence - The ANRS CUPILT study.Role of cytokine levels in assessment of prognosis and post-treatment outcome in hepatocellular carcinoma.Early Introduction of Subcutaneous Hepatitis B Immunoglobulin Following Liver Transplantation for Hepatitis B Virus Infection: A Prospective, Multicenter Study.Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge.
P50
Q22299427-4ADF0D34-F723-4196-AA5C-37E163625FEDQ26822887-62AC0C5F-3864-47D1-903A-BC5079D34D85Q30235146-40AA8AF7-ADD5-41C2-B65B-77F02A05E90AQ33370788-D8752910-D63F-47FB-A736-A7DD937F2D98Q33861757-7A29800A-AE45-4F2D-A22A-330F73D93E5FQ34157424-AF8C15A6-0C7E-40E3-B81F-FF38F74D3817Q35160315-3DA84935-868B-45D7-99BB-0D9F72A278F9Q35621731-99C094EA-F898-4914-9199-4FC05BC53309Q35635308-FAE077B4-8201-4044-9E5A-3893E162B2D4Q35707214-29E56B0D-787D-4195-8BE1-3C006302FA15Q35755799-DF1EE10E-0B6B-4EC5-B410-B374F0DCDE9FQ35894616-301DB666-6904-44DD-8781-18B991B51A65Q35974721-43FF20D3-A689-45C6-945C-CF9CAC9BADF3Q36421630-0F217CE7-7FF1-4F88-9D73-765A4756497FQ36903588-BBF7C415-F982-46F4-AFD3-45A24F027F77Q37282534-6ADD617B-A47E-4E57-BB64-D29FA98CACF9Q37383787-42863B5F-A83A-43EB-BC44-E8738D1D161EQ37577568-3388364C-8524-477B-B0AF-016D7C7ABD79Q37893109-60F3CDE9-54B0-4303-AE73-93AFA12036E9Q37920857-AFF84E97-2376-4924-A240-4F349B12C0E5Q37972771-23B8D2EA-1B6C-4681-9CF7-BBBE3A8D0D3CQ38039011-632E8374-9E70-4B83-8099-190CD4CBA3B9Q38125740-F21B1881-697D-4F88-9B61-988973F235B1Q38174249-C6268AF2-0D8C-4119-B766-582EC4219F02Q38451823-1C73E184-A98B-4297-BFF9-6974897F184EQ38514411-9CDDB383-C1EB-4091-A955-6F19F183A8FDQ39082532-67A7573D-0663-4E83-9312-E59E745C0F13Q39138958-1429B105-AB34-4681-8A18-4E24AB4B704BQ39190047-6646AC7B-F5CF-4192-9B97-6F6B2B7200A3Q39388862-9135AD30-3580-462F-B7F2-68FFB0349575Q40241924-86AEF231-51D4-4230-B732-04D859C811DEQ40319656-E5A7F226-A801-49DD-942B-6C40CEDD636AQ40495828-52F1AD7C-928C-4D4F-A9C7-5BC39BBECD0AQ40542074-F52773A1-14F0-4975-8661-2A5B4C812AA4Q40634052-FDB18568-2944-4F97-8B8B-4681B8B1F994Q40635393-E356BF33-63CA-4CC3-AF34-B3B7E5507EAFQ40645429-7906A915-B16B-4FCF-89D2-5688F0B63CE2Q40707004-7554E78F-97A4-497C-81F7-16E6BB144CC8Q40737426-14C4937E-56AC-4D07-943B-ABCCE62BC62CQ41064083-44ED7235-1F1F-48D7-B99C-4351432EE780
P50
description
researcher ORCID ID = 0000-0001-9481-3616
@en
wetenschapper
@nl
name
Didier Samuel
@ast
Didier Samuel
@en
Didier Samuel
@es
Didier Samuel
@nl
type
label
Didier Samuel
@ast
Didier Samuel
@en
Didier Samuel
@es
Didier Samuel
@nl
prefLabel
Didier Samuel
@ast
Didier Samuel
@en
Didier Samuel
@es
Didier Samuel
@nl
P106
P31
P496
0000-0001-9481-3616